Research

Researchers at Weill Cornell Medicine have discovered how a parasite that causes malaria when transmitted through a mosquito bite can hide from the body’s immune system, for years sometimes.

Weill Cornell Medicine is fostering a new generation of researchers in Tanzania, with implications for improved health care outcomes worldwide.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian that compared the safety and efficacy of the injectable drugs. 

A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine.

Dr. David C. Lyden received the prestigious Special Achievement Award from the International Society for Extracellular Vesicles 

Weill Cornell Medicine has received a projected $4 million grant from the National Cancer Institute, part of the National Institutes of Health, to conduct a clinical trial testing whether a new imaging approach could reduce the need for biopsies to monitor prostate cancer.

Using machine learning technology, a new study has identified three distinct profiles describing social and economic factors that are associated with a higher risk of suicide.

A tiny chemical modification commonly found on messenger RNAs plays a surprisingly large role in how cells respond to stress, according to a study led by Weill Cornell Medicine investigators.

Teams of health care providers called Accountable Care Organizations participating in the Medicare Shared Savings Program have saved Medicare between $4.1 billion and $8.1 billion from 2012 through 2019, according to a new study from Weill Cornell Medicine investigators. 

Weill Cornell Medicine investigators are developing a new test for TB that circumvents many of the current diagnostic challenges.

A major new effort at Weill Cornell Medicine seeks to catalog the normal human virome, the immense ecosystem of viruses that lives in and on us.

Three distinguished Weill Cornell Medicine physician-scientists, Dr. Matthew Greenblatt, Dr. Lishomwa Ndhlovu and Dr. Sallie Permar, have been elected to the prestigious Association of American Physicians (AAP).

A new study from Weill Cornell Medicine provides insights into how cells maintain the tiny end caps of chromosomes as they divide, a key process in keeping cells healthy. Using yeast, the researchers reveal protein interactions that could explain how the enzyme telomerase is tightly regulated to prevent cells from dividing uncontrollably or aging prematurely.

The way DNA folds inside the nucleus of brain cells may hold the key to understanding a devastating form of brain cancer called glioblastoma, suggests a new preclinical study from Weill Cornell Medicine researchers.

Bacteria naturally present in the human intestine, known as the gut microbiota, can transform cholesterol-derived bile acids into powerful metabolites that strengthen anti-cancer immunity by blocking androgen signaling, according to a preclinical study led by Weill Cornell Medicine investigators.

As chair, Dr. Ehrt seeks to build on the department’s already robust national and international footprint in tuberculosis research and expand its portfolio in other areas of research and innovation.

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following treatment, according to a study by Weill Cornell Medicine and New York Genome Center investigators.

New research from Weill Cornell Medicine has uncovered a surprising culprit underlying cardiovascular diseases in obesity and diabetes—not the presence of certain fats, but their suppression.

Dr. Timothy Ryan has been named one of eight academic principal investigators to participate in the SPARK NS Translational Research Program, 2025 cohort.

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic pontine glioma (DIPG) is safe, reported Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center investigators.